Lonza Adds Spray-Drying Lines in Bend as CDMO Capacity Race Widens

Lonza said it will build a new commercial spray-drying facility in Bend, Oregon, expanding its US manufacturing footprint, while Samsung Biologics disclosed a $262 million manufacturing contract, according to Endpoints News on Sept. 10, 2026.

Two of the largest names in pharmaceutical contract manufacturing moved on the same day, and in the same direction: more capacity, more of it committed in advance. Lonza said it will build a new commercial spray-drying facility at its site in Bend, Oregon, adding to a US footprint that has become the industry's default answer to supply-chain and policy risk. Samsung Biologics separately disclosed a manufacturing contract worth $262 million.

Neither item is a scientific breakthrough. Both are, in the current environment, more consequential than most readouts. Drug developers cannot commercialize what they cannot manufacture, and the queue for validated commercial-scale capacity has been the binding constraint on more than one launch this decade.

What spray-drying capacity in Bend actually buys

Spray drying is a formulation technique, not a fill-finish step. A drug substance that dissolves poorly in water — a large and growing share of small-molecule candidates coming out of discovery — is dissolved in a solvent with a polymer, then atomized into a heated chamber where the solvent flashes off. What drops out is an amorphous solid dispersion: the molecule locked in a form the gut can actually absorb. Without it, a chemically valid drug can simply fail to reach useful blood levels in humans.

Bend is not an arbitrary location for this. The site has long been associated with spray-dried dispersion work, and adding commercial-scale lines is materially different from adding clinical ones. Clinical batches are small, campaign-based and forgiving. Commercial lines have to be validated, inspected, and run reliably for years against a marketed product's demand forecast. Building them is a bet that the pipeline of poorly soluble small molecules now in late-stage development converts into approvals that need supply.

The details of the investment — dollar value, headcount, and the date the lines come online — were reported by Endpoints News, which also carried the Samsung Biologics contract and separate news on Boston Scientific.

A $262 million contract is a capacity reservation

Samsung Biologics' $262 million agreement belongs to a category of disclosure that has become routine for the South Korean manufacturer: a single named contract, sized in the hundreds of millions, covering multi-year commercial supply. These deals are less about the manufacturer winning a price negotiation than about the customer buying certainty. A biologics sponsor with a product heading toward approval needs suites locked in years ahead of the launch date, because the alternative — scrambling for capacity after a regulatory decision — is how launches get rationed.

For investors, the read-through is on backlog quality rather than any single quarter. Contract manufacturers convert signed agreements to revenue over long horizons, and the size of the committed book tells you more about the next three years than the current one. It also tells you something about the customer base: contracts of this scale are not signed by preclinical biotechs.

Onshoring has stopped being a talking point

The strategic logic behind both announcements is the same. Pharmaceutical supply chains that ran through a small number of overseas nodes have been under political and commercial pressure for several years, and the industry's response has been to duplicate capability inside the United States rather than argue about it. Building in Oregon is expensive relative to the alternatives. It is also unarguable in front of a regulator, a customer, or a legislator.

What makes the CDMO buildout distinctive is who is carrying the capital risk. When a manufacturer funds a new commercial line, it is absorbing the fixed cost so its pharma customers do not have to put it on their own balance sheets. That is an attractive trade when utilization is high and a punishing one when it is not. The industry's history includes both conditions, sometimes within the same cycle, which is why the announcements worth watching are the ones tied to committed volume rather than speculative square footage.

Boston Scientific trades lower against a soft tape

The same Endpoints roundup carried news on Boston Scientific. Shares of BSX were quoted at 43.84 as of the last trade at 16:29 GMT on Sept. 10, 2026, down 2.49% from the previous close of 44.96, and near the bottom of a session range of 43.76 to 44.42.

That move came against a broadly negative tape rather than in isolation. The S&P 500 tracker (NYSEARCA: SPY) was at $758.00, off 0.58% from a prior close of $762.40. The Nasdaq 100 fund (NASDAQ: QQQ) sat at $709.47, down 0.95% from $716.31, and the Dow tracker (NYSEARCA: DIA) was at $520.81, down 0.62% from $524.07. Boston Scientific's decline was therefore steeper than any of the three benchmarks on the day — roughly four times the S&P 500's percentage move, on an illustrative basis using the figures above — but the direction was shared with the whole market.

What to watch from here

• Timeline to validation. A commercial spray-drying line is only useful once regulators have signed off on the process running in it. The gap between groundbreaking and first commercial batch is where these projects succeed or disappoint.
• Utilization disclosure. Capacity announcements are easy; occupancy is the number that matters. Watch whether manufacturers pair new builds with named customers or leave them uncommitted.
• Backlog conversion. Samsung Biologics' $262 million contract will be recognized over time. The question is what proportion of the total order book is with sponsors that already have approved products.
• Small-molecule mix. Spray drying serves oral small molecules. Continued investment there is a quiet vote of confidence that the small-molecule pipeline — including oral versions of drug classes previously delivered by injection — keeps growing.

The pattern across both announcements is consistent. The manufacturing layer of the drug industry is being rebuilt closer to the end market, funded largely by the manufacturers themselves, and increasingly sold before it is finished. That is a healthier structure than speculative expansion, but it concentrates the consequences: if demand forecasts slip, the capacity is already poured.

Key facts

• Lonza project: New commercial spray-drying facility in Bend, Oregon
• Samsung Biologics contract: $262 million manufacturing agreement
• BSX last trade: 43.84, -2.49% as of 16:29 GMT, Sept. 10, 2026
• Market backdrop: SPY $758.00 (-0.58%), QQQ $709.47 (-0.95%), DIA $520.81 (-0.62%)

Frequently asked questions

What is spray drying and why do drugmakers need it?

Spray drying dissolves a drug substance with a polymer in solvent, then atomizes the mixture into heated air so the solvent evaporates instantly. The result is an amorphous solid dispersion that the body can absorb. It is used for molecules that dissolve poorly in water, a large share of modern small-molecule candidates that would otherwise fail to reach useful blood concentrations when taken orally.

Where is Lonza building the new facility?

Lonza said it is adding a new commercial spray-drying facility in Bend, Oregon, expanding its United States manufacturing capacity. The Bend site has an established association with spray-dried dispersion work. Moving to commercial scale, rather than clinical scale, means the lines must be validated and inspected for sustained production of a marketed product over many years.

How large is the Samsung Biologics contract?

Samsung Biologics disclosed a manufacturing contract valued at $262 million. Agreements of this size are typically multi-year commercial supply arrangements in which a drug sponsor reserves capacity ahead of a product launch. Revenue from such contracts is recognized over the life of the agreement rather than in a single reporting period.

How did Boston Scientific shares trade on the day?

BSX was quoted at 43.84 as of the last trade at 16:29 GMT on Sept. 10, 2026, down 2.49% from a previous close of 44.96. The session range was 43.76 to 44.42, leaving the stock near its intraday low. The decline was steeper than the major US equity benchmarks, all of which were also lower that session.

What is a CDMO?

A contract development and manufacturing organization makes drugs on behalf of pharmaceutical and biotech companies. CDMOs handle process development, scale-up, and commercial production, letting sponsors avoid building and validating their own plants. Lonza and Samsung Biologics are two of the largest, serving both small-molecule and biologics customers under long-term supply agreements.

Why are drug manufacturers expanding inside the United States?

Pharmaceutical supply chains concentrated in a small number of overseas locations have faced sustained political and commercial pressure. Duplicating capability inside the US reduces exposure to trade and policy disruption and reassures customers and regulators. The trade-off is cost: domestic construction and operating expenses are generally higher, so the economics depend on keeping the new capacity well utilized.

Sources

• Lonza to build new US factory; Samsung Bio signs $262M contract — Endpoints News

Photo: Amornthep Srina · Pexels Licence — source